Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | ATR | Q13535 | 1/20 | 0.40 |
| ▸ | KDM5A | P29375 | 2/20 | 0.40 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.40 |
| ▸ | GAK | O14976 | 1/20 | 0.40 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.40 |
| ▸ | COQ8A | Q8NI60 | 1/20 | 0.40 |
| ▸ | NLK | Q9UBE8 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30647715 | 1.00 | LMNA (0.48) | LMNAKDM4EPSMD14CYP11B2AR | |
| SCHEMBL26965972 | 0.89 | PSMD14 (0.43) | LMNAKDM4EPSMD14CYP11B2AR | |
| SCHEMBL26965991 | 0.88 | LMNA (0.47) | LMNAKDM4EPSMD14ATRKDM5A | |
| SCHEMBL30647720 | 0.88 | LMNA (0.47) | LMNAKDM4EPSMD14ATRKDM5A | |
| SCHEMBL22492480 | 0.86 | CFTR (0.54) | LMNAKDM4EPSMD14GAKRIPK2 | |
| SCHEMBL31510515 | 0.84 | LMNA (0.58) | LMNAKDM4EKDM5AKDM5BL3MBTL1 | |
| SCHEMBL31510539 | 0.83 | KDM4E (0.41) | LMNAKDM4EPSMD14CYP11B2KDM5A | |
| SCHEMBL32684875 | 0.83 | KDM4E (0.41) | LMNAKDM4EPSMD14CYP11B2KDM5A | |
| SCHEMBL27371112 | 0.80 | LMNA (0.50) | LMNAKDM4EPSMD14KDM5AHTT | |
| SCHEMBL24728976 | 0.80 | LMNA (0.52) | LMNAKDM4EPSMD14ATRKDM5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4543869-B1 | N-(2-(3-CYANO-2-AZABICYCLO[3.1.0]HEXAN-2-YL)-2-OXOETHYL)- QUINOLINE-4-CARBOXAMIDES | ASTRAZENECA AB (SE) | 2026-05-27 | — | — | EP | disclosed |
| US-20260070899-A1 | N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-QUINOLINE-4-CARBOXAMIDES | ASTRAZENECA AB (SE) | 2026-03-12 | — | — | US | disclosed |
| EP-4543878-A1 | N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)- QUINOLINE-4-CARBOXAMIDES | Astrazeneca AB (SE) | 2025-04-30 | — | — | EP | disclosed |
| EP-4543869-A1 | N-(2-(3-CYANO-2-AZABICYCLO[3.1.0]HEXAN-2-YL)-2-OXOETHYL)- QUINOLINE-4-CARBOXAMIDES | Astrazeneca AB (SE) | 2025-04-30 | — | — | EP | disclosed |
| CN-119562951-A | N- (2- (4-cyanothiazolidin-3-yl) -2-oxoethyl) -quinoline-4-carboxamide | 阿斯利康(瑞典)有限公司 | 2025-03-04 | — | — | CN | disclosed |
| CN-119562947-A | N- (2- (3-cyano-2-azabicyclo [3.1.0] hex-2-yl) -2-oxoethyl) -quinoline-4-carboxamide | 阿斯利康(瑞典)有限公司 | 2025-03-04 | — | — | CN | disclosed |
| WO-2023247489-A1 | N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)- QUINOLINE-4-CARBOXAMIDES | ASTRAZENECA AB (SE) | 2023-12-28 | — | — | WO | disclosed |
| WO-2023247488-A1 | N-(2-(3-CYANO-2-AZABICYCLO[3.1.0]HEXAN-2-YL)-2-OXOETHYL)- QUINOLINE-4-CARBOXAMIDES | ASTRAZENECA AB (SE) | 2023-12-28 | — | — | WO | disclosed |
| US-20230406840-A1 | N-(2-(3-CYANO-2-AZABICYCLO[3.1.0]HEXAN-2-YL)-2-OXOETHYL)QUINOLINE-4-CARBOXAMIDES | ASTRAZENECA AB (SE) | 2023-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070899-A1 | N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-QUINOLINE-4-CARBOXAMIDES | FAP, CTRL, CTSC | LMNA 1315/4885KDM4E 2933/4885PSMD14 4709/4885 |
| US-20230406840-A1 | N-(2-(3-CYANO-2-AZABICYCLO[3.1.0]HEXAN-2-YL)-2-OXOETHYL)QUINOLINE-4-CARBOXAMIDES | FAP, PREP, HEXA | LMNA 1386/4885KDM4E 669/4885PSMD14 4337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.